Evidence Hub

Daily tadalafil: efficacy and safety of a new dosing regimen

B. Giammusso

Sexologies, 2008

1 citation

Abstract

Tadalafil is a selective, reversible phosphodiesterase type 5 inhibitor with demonstrated efficacy as an oral treatment for erectile dysfunction (ED). The molecule possesses a favourable pharmacokinetic profile, with a rapid onset of action and prolonged duration of proerectile effects. The pharmacokinetics characteristics of tadalafil are amenable to once-a-day dosing, which may be an attractive alternative treatment for patients with ED. Two randomized, placebo-controlled, double-blind studies in men with ED showed that 2.5-10 mg tadalafil once daily significantly improved erectile function compared with placebo, after 12 or 24 weeks. In two open-label extensions of these studies, the efficacy of tadalafil was maintained over a two year treatment period, suggesting lack of tolerance. In terms of safety, tadalafil administered daily was well tolerated, did not affect cardiovascular safety, and demonstrated lack of toxicity on spermatogenesis.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free